Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovaza Add-on to Antara in Hypertriglyceridemia
NCT00246636Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia (3 arms), sponsored by GSK. Primary endpoint: Percent change in fasting serum triglyceride level at 8 weeks. Started Oct 2005; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT00246636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246636.